Terms: = Bone cancer AND HSP90AB1, HSPCB, 3326, ENSG00000096384, HSP90B, HSP90-BETA, P08238, D6S182, HSPC2, FLJ26984 AND Treatment
4 results:
1. Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs.
Li K; Sun X; Zha R; Liu S; Feng Y; Sano T; Aryal UK; Sudo A; Li BY; Yokota H
Theranostics; 2022; 12(7):3084-3103. PubMed ID: 35547745
[No Abstract] [Full Text] [Related]
2. Suppression of breast cancer-associated bone loss with osteoblast proteomes via hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling.
Sun X; Li K; Hase M; Zha R; Feng Y; Li BY; Yokota H
Theranostics; 2022; 12(2):929-943. PubMed ID: 34976221
[No Abstract] [Full Text] [Related]
3. Screening of disorders associated with osteosarcoma by integrated network analysis.
Dou Y; Zhu K; Sun Z; Geng X; Fang Q
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30936265
[TBL] [Abstract] [Full Text] [Related]
4. Secondary head and neck cancer in patients with history of hematological malignancy.
Chung JC; Tsang RK; To VS; Ho AC; Chan JY; Ho WK; Wei WI
Head Neck; 2013 May; 35(5):729-32. PubMed ID: 22585675
[TBL] [Abstract] [Full Text] [Related]
